Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight

Research output: Contribution to journalReviewResearchpeer-review

Standard

Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight. / Huang, Lam Opal; Loos, Ruth; Oskari Kilpeläinen, Tuomas.

In: Physiological Genomics, Vol. 50, No. 3, 2018, p. 169-178.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Huang, LO, Loos, R & Oskari Kilpeläinen, T 2018, 'Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight', Physiological Genomics, vol. 50, no. 3, pp. 169-178. https://doi.org/10.1152/physiolgenomics.00044.2017

APA

Huang, L. O., Loos, R., & Oskari Kilpeläinen, T. (2018). Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight. Physiological Genomics, 50(3), 169-178. https://doi.org/10.1152/physiolgenomics.00044.2017

Vancouver

Huang LO, Loos R, Oskari Kilpeläinen T. Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight. Physiological Genomics. 2018;50(3):169-178. https://doi.org/10.1152/physiolgenomics.00044.2017

Author

Huang, Lam Opal ; Loos, Ruth ; Oskari Kilpeläinen, Tuomas. / Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight. In: Physiological Genomics. 2018 ; Vol. 50, No. 3. pp. 169-178.

Bibtex

@article{8e749a28b10847e7ac157186512475a0,
title = "Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight",
abstract = "Obesity has evolved into a global pandemic that constitutes a major threat to public health. The majority of obesity-related health care costs are due to cardiometabolic complications, such as insulin resistance, dyslipidemia, and hypertension, which are risk factors for Type 2 diabetes and cardiovascular disease. However, many obese individuals, often called metabolically healthy obese (MHO), seem to be protected from these cardiometabolic complications. Conversely, there is a group of individuals who suffer from cardiometabolic complications despite being of normal weight; a condition termed metabolically obese normal weight (MONW). Recent large-scale genomic studies have provided evidence that a number of genetic variants show an association with increased adiposity but a favorable cardiometabolic profile, an indicator for the genetic basis of the MHO and MONW phenotypes. Many of these loci are located in or near genes that implicate pathways involved in adipogenesis, fat distribution, insulin signaling, and insulin resistance. It has been suggested that a threshold for subcutaneous adipose tissue expandability may be at play in the manifestation of MHO and MONW, where expiry of adipose tissue storage capacity could lead to ectopic lipid accumulation in non-adipose tissues such as liver, muscle, heart, and pancreatic beta cells. Understanding the genetic aspects of the mechanisms that underpin MHO and MONW is crucial to define appropriate public health action points and to develop effective intervention measures.",
author = "Huang, {Lam Opal} and Ruth Loos and {Oskari Kilpel{\"a}inen}, Tuomas",
year = "2018",
doi = "10.1152/physiolgenomics.00044.2017",
language = "English",
volume = "50",
pages = "169--178",
journal = "Physiological Genomics",
issn = "1094-8341",
publisher = "American Physiological Society",
number = "3",

}

RIS

TY - JOUR

T1 - Evidence of genetic predisposition for metabolically healthy obesity and metabolically obese normal weight

AU - Huang, Lam Opal

AU - Loos, Ruth

AU - Oskari Kilpeläinen, Tuomas

PY - 2018

Y1 - 2018

N2 - Obesity has evolved into a global pandemic that constitutes a major threat to public health. The majority of obesity-related health care costs are due to cardiometabolic complications, such as insulin resistance, dyslipidemia, and hypertension, which are risk factors for Type 2 diabetes and cardiovascular disease. However, many obese individuals, often called metabolically healthy obese (MHO), seem to be protected from these cardiometabolic complications. Conversely, there is a group of individuals who suffer from cardiometabolic complications despite being of normal weight; a condition termed metabolically obese normal weight (MONW). Recent large-scale genomic studies have provided evidence that a number of genetic variants show an association with increased adiposity but a favorable cardiometabolic profile, an indicator for the genetic basis of the MHO and MONW phenotypes. Many of these loci are located in or near genes that implicate pathways involved in adipogenesis, fat distribution, insulin signaling, and insulin resistance. It has been suggested that a threshold for subcutaneous adipose tissue expandability may be at play in the manifestation of MHO and MONW, where expiry of adipose tissue storage capacity could lead to ectopic lipid accumulation in non-adipose tissues such as liver, muscle, heart, and pancreatic beta cells. Understanding the genetic aspects of the mechanisms that underpin MHO and MONW is crucial to define appropriate public health action points and to develop effective intervention measures.

AB - Obesity has evolved into a global pandemic that constitutes a major threat to public health. The majority of obesity-related health care costs are due to cardiometabolic complications, such as insulin resistance, dyslipidemia, and hypertension, which are risk factors for Type 2 diabetes and cardiovascular disease. However, many obese individuals, often called metabolically healthy obese (MHO), seem to be protected from these cardiometabolic complications. Conversely, there is a group of individuals who suffer from cardiometabolic complications despite being of normal weight; a condition termed metabolically obese normal weight (MONW). Recent large-scale genomic studies have provided evidence that a number of genetic variants show an association with increased adiposity but a favorable cardiometabolic profile, an indicator for the genetic basis of the MHO and MONW phenotypes. Many of these loci are located in or near genes that implicate pathways involved in adipogenesis, fat distribution, insulin signaling, and insulin resistance. It has been suggested that a threshold for subcutaneous adipose tissue expandability may be at play in the manifestation of MHO and MONW, where expiry of adipose tissue storage capacity could lead to ectopic lipid accumulation in non-adipose tissues such as liver, muscle, heart, and pancreatic beta cells. Understanding the genetic aspects of the mechanisms that underpin MHO and MONW is crucial to define appropriate public health action points and to develop effective intervention measures.

U2 - 10.1152/physiolgenomics.00044.2017

DO - 10.1152/physiolgenomics.00044.2017

M3 - Review

C2 - 29341865

VL - 50

SP - 169

EP - 178

JO - Physiological Genomics

JF - Physiological Genomics

SN - 1094-8341

IS - 3

ER -

ID: 222167012